These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 38420602)

  • 21. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
    Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than
    Seegobin K; Majeed U; Wiest N; Manochakian R; Lou Y; Zhao Y
    Front Oncol; 2021; 11():750657. PubMed ID: 34926258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex- and Age-Associated Differences in Genomic Alterations among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC).
    Kimbrough EO; Marin-Acevedo JA; Drusbosky LM; Mooradian A; Zhao Y; Manochakian R; Lou Y
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
    Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations.
    Chen L; Xie J; Zhu M; Wang D; Liu H; Zhan P; Yin J; Ye M; Song Y; Lv T
    Transl Cancer Res; 2024 Jan; 13(1):137-149. PubMed ID: 38410222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET , or RET Alterations: A Systematic Literature Review.
    Akers KG; Oskar S; Zhao B; Frederickson AM; Arunachalam A
    J Immunother; 2024 May; 47(4):128-138. PubMed ID: 38112201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.
    Cefalì M; Epistolio S; Ramelli G; Mangan D; Molinari F; Martin V; Freguia S; Mazzucchelli L; Froesch P; Frattini M; Wannesson L
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of immunotherapy in
    Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
    Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
    Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
    J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
    Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
    J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
    Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
    Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
    BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 40. Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
    Li D; Ding L; Ran W; Huang Y; Li G; Wang C; Xiao Y; Wang X; Lin D; Xing X
    Thorac Cancer; 2020 Sep; 11(9):2580-2589. PubMed ID: 32729257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.